Core Insights - The article emphasizes the value of in-depth analysis in the Biotech sector, highlighting the services offered by Biotech Analysis Central, which includes a library of over 600 articles and a model portfolio of small and mid-cap stocks [2] Group 1 - The Biotech Analysis Central service is available for $49 per month, with a discounted annual plan at $399, representing a 33.50% savings for subscribers [1] - The service aims to assist healthcare investors in making informed decisions through comprehensive analysis and news reports [2] - The author has a background in Applied Science, which is leveraged to generate long-term value in the healthcare sector [2]

Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. for alleged misleading statements regarding its New Drug Application for Anaphylm, affecting investors who purchased securities between June 16, 2025, and January 8, 2026 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Aquestive made false and/or misleading statements and failed to disclose critical information about its New Drug Application for Anaphylm, particularly regarding human factors related to its sublingual film [5]. - Investors are encouraged to join the class action, which allows them to seek compensation without upfront costs through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by May 4, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Viatris Inc. (NASDAQ:VTRS) is recognized as one of the best stocks under $20 to buy according to hedge funds, with recent price target increases from UBS and BofA indicating positive market sentiment towards the company [1][3]. Group 1: Price Target Adjustments - UBS raised its price target on Viatris from $18 to $20 while maintaining a Buy rating, citing the company's achievement of cost-saving targets and fiscal year 2026 guidance exceeding analysts' expectations [1]. - BofA increased its price target from $10 to $12 but maintained an Underperform rating, reflecting a cautious outlook despite acknowledging the company's cost-cutting efforts [3]. Group 2: Cost-Saving Initiatives - Viatris plans to achieve approximately $400 million in net cost reductions over three years, with about half of the savings expected to come from lowering the cost of goods sold [3]. - UBS believes that the upcoming investor event on March 19 could provide a foundation for long-term mid-single-digit revenue growth targets, supported by the company's cost-saving initiatives [2]. Group 3: Growth Potential - UBS anticipates that Viatris can deliver EPS growth at a compound annual growth rate in the teens during its next growth phase, which could lead to a higher valuation multiple for the stock [2]. - The company's focus on providing access to generic and brand-name medicines across various therapeutic areas positions it well for future growth [4].

Bayer AG (OTCMKTS:BAYRY) is among the best German stocks to buy according to analysts. On March 5, Bayer AG (OTCMKTS:BAYRY) announced that the FDA has cleared its MEDRAD MRXperion MR injector system for expanded application. That means this contrast injector system can now be used across a broader range of MRI scanners, including those with magnetic fields up to 7 Tesla. Bayer AG (BAYRY) Receives FDA Approval For Expanded MR Injector Application Bayer’s MEDRAD MRXperion is used in MRI diagnostic procedur ...

Core Viewpoint - Novartis' Cosentyx (secukinumab) has received FDA approval for treating pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa (HS), marking it as the only IL-17A inhibitor available for this demographic [1][6]. Group 1: Product Approval and Significance - The approval of Cosentyx provides a distinct biologic treatment option for pediatric patients with HS, allowing for tailored treatment approaches [1][4]. - This marks the fourth pediatric indication for Cosentyx, reinforcing its established safety and efficacy profile [6]. Group 2: Impact on Patients and Healthcare - HS often begins in adolescence and can lead to irreversible scarring and disabilities, highlighting the need for early intervention [2][7]. - The approval is seen as a significant advancement for younger patients who have had limited treatment options, bringing hope for improved management of the condition [3][4]. Group 3: Mechanism and Dosing - Cosentyx operates through a differentiated IL-17A mechanism, providing physicians with a new therapeutic option for managing HS in younger patients [3][6]. - The dosing for patients aged 12 and older weighing 30 kg or more is supported by adult studies and pharmacokinetic modeling, ensuring similar exposure levels to adult HS patients [3][5]. Group 4: Company Background - Novartis has over a decade of real-world experience with Cosentyx across multiple autoimmune diseases, establishing it as a trusted treatment option among physicians [4][5]. - Since its launch in 2015, Cosentyx has treated over 1.8 million patients globally and is approved in more than 100 countries [5].

Core Insights - Blackstone Inc. is recognized as one of the top 10 best asset management stocks to buy currently [1] Group 1: Investment and Strategic Partnerships - Blackstone Life Sciences has entered a strategic funding agreement worth $400 million with Teva Pharmaceuticals to accelerate the clinical development of duvakitug, a monoclonal antibody targeting TL1A [2] - The investment will be distributed over four years, with Blackstone set to receive regulatory milestones and low single-digit global royalties upon FDA approval [2] Group 2: Clinical Development and Market Potential - Duvakitug is positioned as a potential best-in-class therapy in a significant and expanding market, with ongoing Phase 3 trials for ulcerative colitis and Crohn's disease following successful Phase 2b data [3] - The collaboration between Teva and Sanofi is highlighted as well-positioned to develop and commercialize this important medicine [3] Group 3: Analyst Coverage and Market Outlook - Barclays analyst Benjamin Budish has reinstated coverage of Blackstone with an Equal Weight rating and a price target of $126, maintaining unchanged ratings and earnings estimates [3]

Core Viewpoint - The Court has granted preliminary approval for a $65 million settlement in an antitrust class action against Actelion Pharmaceuticals, now part of Johnson & Johnson, for allegedly preventing generic drug manufacturers from developing a cheaper version of its drug Tracleer [1] Group 1: Lawsuit Details - The lawsuit was initiated by the Government Employees Health Association (GEHA), which claimed that Actelion obstructed generic manufacturers from obtaining necessary samples of Tracleer, thereby hindering the market entry of generic alternatives [2] - GEHA alleged that Actelion not only refused to sell samples but also contractually prevented competitors from acquiring samples from pharmacies, effectively blocking all avenues for generic manufacturers [2] - The alleged actions resulted in no generic product being available for nearly four years after the Tracleer patent expired, leading to over $100 million in overpayments by GEHA and other Third-Party Payors for the drug [2] Group 2: Settlement and Impact - The settlement amount of $65 million represents nearly 50% of the conservative single damages estimate, providing significant relief to the class of entities that purchased Tracleer [3] - If finalized, the settlement will resolve over seven years of litigation and deliver compensation to those affected by the alleged antitrust practices [3] Group 3: Drug Information - Tracleer, the brand name for bosentan, is used to treat pulmonary artery hypertension (PAH), a chronic and potentially fatal condition affecting 10,000 to 20,000 people in the U.S., primarily women [4] - At the time of the alleged antitrust scheme, Actelion charged $75,000 per patient annually for Tracleer [4] Group 4: Legal Proceedings - The lawsuit was originally filed in 2018 but was dismissed in 2019 due to statute of limitations issues; however, the Fourth Circuit revived the case in 2021, allowing it to proceed [5] - The district court granted class certification for GEHA in September 2024, denying Actelion's motion for summary judgment, which set the stage for the trial [5]

Core Insights - United Therapeutics (UTHR) shares have increased approximately 32% over the past six months due to strong commercial growth, a significant clinical breakthrough, and enhanced long-term growth visibility, boosting investor confidence [1] Financial Performance - UTHR reported better-than-expected earnings for Q4 2025, with annual revenues nearing $3.2 billion, primarily driven by the rapid adoption of its flagship drug Tyvaso, especially the dry-powder inhaler (DPI) version [2][3] - The company ended 2025 with $4.6 billion in cash and no debt, indicating strong financial health [8][11] - UTHR anticipates double-digit revenue growth in 2026 and aims to reach a $4 billion annual revenue run-rate in the second half of 2027 [12] Product Performance - Tyvaso has become the primary growth engine for United Therapeutics, with combined sales growing 16% year over year in 2025, and Tyvaso DPI sales increasing by 25% year over year [3] - Positive data from the Phase III TETON-2 study showed significant improvements in lung function for patients with idiopathic pulmonary fibrosis (IPF), which could expand Tyvaso's therapeutic reach and revenue potential [5][6] Pipeline Developments - United Therapeutics is conducting the Phase III TETON-1 study of nebulized Tyvaso in IPF patients, with data expected in early 2026, and plans to expedite regulatory review with the FDA [9] - The company is also evaluating ralinepag for PAH in the Phase III ADVANCE OUTCOMES study, which met its primary endpoint, with a new drug application planned for submission in the second half of 2026 [10] Market Performance - Over the past year, UTHR shares have rallied 73.4%, significantly outperforming the industry, which saw a 1.6% decline [4]

Management View - Acurx Pharmaceuticals, Inc. (ACXP) reported a receipt of $1.4 million in gross proceeds from the execution of Series F Warrants in October 2025 [2] - The company is preparing to launch a pivotal recurrent CDI trial in the second half of 2026 while also strengthening its ibezapolstat pipeline [2]

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights (1)28 February 2026 83,814,526 Gross total* of voting rights: 131,963,662Net total** of voting ...